Unidimensional Neanderthal
FrugalEbenezer
My 2 cents on Xbrane Biopharma (Not investment advice, DYODD; Disclaimer: I'm long $XBRANE): The central two questions are:1. Will their lead candidate Xlucane (biosimilar referencing Lucentis) make it to
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.